Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tumor-infiltrating lymphocytes (Shanghai OriginCell Therapeutics)
- Development stage
- Unknown
- Lead developer
- OriCell Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous tumor-infiltrating lymphocytes (TILs) developed by Shanghai OriginCell Therapeutics are an adoptive cell therapy being investigated for the treatment of recurrent and refractory non-small cell lung cancer (NSCLC). The therapeutic process involves the surgical resection of a patient's tumor tissue to isolate naturally occurring T cells that have already infiltrated the tumor microenvironment. These cells are then expanded to large quantities ex vivo in a specialized manufacturing facility using growth factors like interleukin-2 (IL-2). Once expanded, the polyclonal TIL population—which is capable of recognizing a diverse array of patient-specific tumor neoantigens—is re-infused into the patient following a lymphodepleting chemotherapy regimen. This approach aims to overcome tumor heterogeneity and provide a robust, personalized anti-tumor immune response.
- Other names
- Autologous TILsTumor-infiltrating lymphocytesOri-TIL
02
Targets
MHC I (MHC class I})
Beyond the preview
Go deeper on autologous tumor-infiltrating lymphocytes (Shanghai OriginCell Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tumor-infiltrating lymphocytes (Shanghai OriginCell Therapeutics).